Leerink Partnrs Has Pessimistic Outlook of TNDM Q2 Earnings

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) - Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Tandem Diabetes Care in a note issued to investors on Wednesday, April 30th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will post earnings per share of ($0.32) for the quarter, down from their prior forecast of ($0.26). The consensus estimate for Tandem Diabetes Care's current full-year earnings is ($1.68) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care's Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at $0.01 EPS, FY2026 earnings at ($0.58) EPS and FY2027 earnings at $0.01 EPS.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $234.42 million for the quarter, compared to analysts' expectations of $220.19 million. During the same period in the previous year, the business earned ($0.65) earnings per share. The business's revenue for the quarter was up 22.3% on a year-over-year basis.

Several other brokerages have also recently commented on TNDM. Canaccord Genuity Group boosted their price target on Tandem Diabetes Care from $58.00 to $59.00 and gave the stock a "buy" rating in a research report on Thursday. Citigroup cut shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and reduced their target price for the company from $35.00 to $24.00 in a research report on Tuesday, March 4th. Royal Bank of Canada dropped their price objective on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating for the company in a research note on Thursday, February 27th. Stifel Nicolaus decreased their target price on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a research note on Thursday. Finally, Mizuho began coverage on Tandem Diabetes Care in a report on Thursday, April 10th. They issued a "neutral" rating and a $20.00 price target for the company. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $39.81.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM opened at $21.48 on Monday. The stock has a 50 day moving average of $18.80 and a two-hundred day moving average of $28.53. Tandem Diabetes Care has a 12 month low of $15.75 and a 12 month high of $53.69. The firm has a market cap of $1.43 billion, a P/E ratio of -11.13 and a beta of 1.52. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29.

Insiders Place Their Bets

In other news, COO Jean-Claude Kyrillos bought 10,538 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average price of $18.12 per share, with a total value of $190,948.56. Following the purchase, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.90% of the stock is owned by insiders.

Institutional Trading of Tandem Diabetes Care

Hedge funds have recently made changes to their positions in the business. AlphaQuest LLC lifted its holdings in Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after buying an additional 541 shares in the last quarter. NBC Securities Inc. acquired a new stake in shares of Tandem Diabetes Care in the first quarter valued at $37,000. Jones Financial Companies Lllp raised its stake in shares of Tandem Diabetes Care by 195.8% in the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after acquiring an additional 748 shares in the last quarter. Assetmark Inc. boosted its holdings in Tandem Diabetes Care by 77.5% in the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after purchasing an additional 535 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock worth $65,000 after purchasing an additional 1,101 shares during the period.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.